Cogent Biosciences (COGT) Current Deferred Revenue (2017 - 2020)

Cogent Biosciences' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $312000.0 for Q2 2020.

• In Q2 2020, Current Deferred Revenue fell 97.94% year-over-year to $312000.0; the TTM figure through Jun 2020 stood at $312000.0 (down 97.94% YoY), while the FY2019 annual figure was $1.3 million, down 92.67% from the prior year.
• Current Deferred Revenue was $312000.0 for Q2 2020 at Cogent Biosciences, down from $841000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $20.4 million in Q2 2018 to a low of $312000.0 in Q2 2020.
• Historically, Current Deferred Revenue has averaged $12.0 million across 4 years, with a median of $15.2 million in 2019.
• The sharpest annual moves came in 2018 and 2020: Current Deferred Revenue jumped 160.47% in 2018, then tumbled 97.94% in 2020.
• A 4-year view of Current Deferred Revenue shows it stood at $6.9 million in 2017, then surged by 160.47% to $17.9 million in 2018, then slumped by 92.67% to $1.3 million in 2019, then slumped by 76.27% to $312000.0 in 2020.
• The last three Current Deferred Revenue figures came in at $312000.0 (Q2 2020), $841000.0 (Q1 2020), and $1.3 million (Q4 2019), per Business Quant data.